Preclinical models of hepatosplenic γδ T-cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib

Hemasphere. 2026 Apr 16;10(4):e70345. doi: 10.1002/hem3.70345. eCollection 2026 Apr.
No abstract available

Publication types

  • Letter